pat-sm6 receives orphan drug designationfor mm, page-19

Vogliobene - European orphan drug status is a huge milestone in the PAB journey to date.

US/North American orphan drug status should now just be a formality.

Moreover orphan drug status is a huge vindication - given the peer review process is undertaken by experts (i.e., "conservative" European Specialists and researchers - not known for "rash decisions")in the field of MM - that PAT-SM6 is worthy of fast track status.

All of those long term holders - keep focused on the big picture and don't get distracted by the "day to day noise" - particularly by some of those crazy comments we see from our fellow posters from time to time.

To reiterate - PAB has the potential to be a "mini Mesoblast" in the making and has all the hallmarks and characteristics of a successful early stage biotech story (recognizing that this is by its very nature a risky area to be investing in).